Ultrasound contrast agent Optison has been cleared for sale in the European Union. Amersham Health will begin marketing the echocardiography agent this month. The company obtained comarketing rights to the product from Mallinckrodt in
Ultrasound contrast agent Optison has been cleared for sale in the European Union. Amersham Health will begin marketing the echocardiography agent this month. The company obtained comarketing rights to the product from Mallinckrodt in 2000.
What a New Meta-Analysis Reveals About PET/CT Radiotracers for csPCa
February 6th 2025The PET/CT agent 18F-PSMA-1007 offered the highest surface under the cumulative ranking curve (SUCRA) out of nine radiotracers at the patient and lesion level for detecting clinically significant prostate cancer (csPCa), according to a meta-analysis.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.